These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15529143)

  • 1. Profile: Thomas Lönngren.
    Louët S
    Nat Biotechnol; 2004 Nov; 22(11):1341. PubMed ID: 15529143
    [No Abstract]   [Full Text] [Related]  

  • 2. Profile: Corey Goodman.
    Kling J
    Nat Biotechnol; 2009 Apr; 27(4):308. PubMed ID: 19352358
    [No Abstract]   [Full Text] [Related]  

  • 3. Profile: Jean-Paul Clozel.
    Schmidt C
    Nat Biotechnol; 2007 Feb; 25(2):155. PubMed ID: 17287737
    [No Abstract]   [Full Text] [Related]  

  • 4. Profile: William Haseltine.
    Herrera S
    Nat Biotechnol; 2005 Aug; 23(8):913. PubMed ID: 16082351
    [No Abstract]   [Full Text] [Related]  

  • 5. Profile: Una Ryan.
    Schmidt C
    Nat Biotechnol; 2006 Aug; 24(8):881. PubMed ID: 16900115
    [No Abstract]   [Full Text] [Related]  

  • 6. Profile: Jean Deleage.
    Ratner M
    Nat Biotechnol; 2005 Oct; 23(10):1197. PubMed ID: 16211047
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives: biotechnology in Czech Republic, the past and the future.
    Damborský J; Prokop Z; Kostka M
    Biotechnol J; 2006 May; 1(5):487-90. PubMed ID: 16892283
    [No Abstract]   [Full Text] [Related]  

  • 8. [A powerful leader in changing times. Lessons learnt from a symposium dedicated to Borje Uvnas, professor of pharmacology].
    Boréus L
    Lakartidningen; 2003 Nov; 100(46):3771-3. PubMed ID: 14655335
    [No Abstract]   [Full Text] [Related]  

  • 9. Abe Abuchowski.
    Katsnelson A
    Nat Biotechnol; 2006 Sep; 24(9):1050. PubMed ID: 16964200
    [No Abstract]   [Full Text] [Related]  

  • 10. "Extraordinary Measures": Arrowsmith for the NASDAQ era.
    Weissmann G
    FASEB J; 2010 Apr; 24(4):963-7. PubMed ID: 20356907
    [No Abstract]   [Full Text] [Related]  

  • 11. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 12. Masters of their universe.
    Osborne R; DeFrancesco L
    Nat Biotechnol; 2009 Jun; 27(6):528-30. PubMed ID: 19513053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A brief history of generic substitution in the USA.
    Sullivan CG
    Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
    [No Abstract]   [Full Text] [Related]  

  • 14. An interview with Martin Rosenberg, Ph.D. Interviewed by Vicki Glaser.
    Rosenberg M
    Assay Drug Dev Technol; 2009 Dec; 7(6):537-43. PubMed ID: 20035618
    [No Abstract]   [Full Text] [Related]  

  • 15. Déjà Vu at the FDA.
    Sharfstein J
    Milbank Q; 2017 Jun; 95(2):245-248. PubMed ID: 28378412
    [No Abstract]   [Full Text] [Related]  

  • 16. Mexico, the father of the pill and the race for cortisone.
    Renneberg R
    Biotechnol J; 2008 Apr; 3(4):449-51. PubMed ID: 18412173
    [No Abstract]   [Full Text] [Related]  

  • 17. Interview with Thomas P. Monath, M.D. Interview by Vicki Glaser.
    Monath TP
    Vector Borne Zoonotic Dis; 2005; 5(3):300-4. PubMed ID: 16187902
    [No Abstract]   [Full Text] [Related]  

  • 18. Profile: Alpheus Bingham.
    Wilan K
    Nat Biotechnol; 2007 Oct; 25(10):1072. PubMed ID: 17921979
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing the Gold Standard--Lessons from the History of RCTs.
    Bothwell LE; Greene JA; Podolsky SH; Jones DS
    N Engl J Med; 2016 Jun; 374(22):2175-81. PubMed ID: 27248626
    [No Abstract]   [Full Text] [Related]  

  • 20. Deborah Dunsire.
    Littlehales C
    Nat Biotechnol; 2008 Nov; 26(11):1211. PubMed ID: 18997752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.